痛风患者中别嘌醇与苯溴马隆相关尿路结石风险比较:一项基于人群的队列研究
经倾向性评分匹配后,别嘌醇组尿路结石发生率低于苯溴马隆组(0.87/100人年 vs 1.39/100人年,HR 0.64,95%CI 0.51-0.80),需干预结石风险亦较低(HR 0.61,95%CI 0.43-0.88),该关联在高心血管风险亚组更明显。
要点
- 别嘌醇组尿路结石发生率为0.87/100人年,苯溴马隆组为1.39/100人年。
- 别嘌醇组尿路结石风险低于苯溴马隆组(HR 0.64,95%CI 0.51-0.80)。
- 需干预结石风险别嘌醇组低于苯溴马隆组(HR 0.61,95%CI 0.43-0.88)。
核心结论
- 基于人群的队列研究显示,与苯溴马隆相比,别嘌醇与显著较低的尿路结石风险相关,尤其在高心血管风险患者中更为明显。
主要发现
- 共纳入61300例别嘌醇起始者与经倾向性评分匹配的12260例苯溴马隆起始者(平均年龄59岁,79%为男性)。
- 平均随访322天期间发生619例尿路结石,别嘌醇组发生率为0.87/100人年,苯溴马隆组为1.39/100人年,HR为0.64(95%CI 0.51-0.80)。
- 约44%的尿路结石需要干预,HR为0.61(95%CI 0.43-0.88)。
- 别嘌醇较苯溴马隆的较低风险在各亚组中持续存在,但在高心血管风险亚组较非高心血管风险亚组更明显(交互作用P=0.02)。
关键数值与推荐
- 主要结局为新发尿路结石,次要结局为需干预的结石。
- 采用Cox比例风险模型估计HR和95%CI,基于>80个变量以5:1比例进行倾向性评分匹配。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To compare the risk of urolithiasis in gout patients initiating allopurinol, a xanthine oxidase inhibitor, vs benzbromarone, a uricosuric. METHODS: Using the 2011-20 Korea National Health Insurance Service database, we conducted a cohort study on gout patients initiating allopurinol vs benzbromarone as the first-line urate-lowering treatment. The primary outcome was a new onset urinary stone. The secondary outcome was a stone requiring intervention. We estimated hazard ratios (HRs) and 95% CIs using Cox proportional hazard models with a 5:1 ratio propensity-score matching on >80 variables. Subgroup analyses were done by age, sex, thiazide use and cardiovascular risk. RESULTS: 61 300 allopurinol initiators PS-matched on 12 260 benzbromarone initiators were included (mean age 59 years, 79% male). During a mean follow-up of 322 days, 619 urolithiasis cases occurred with an incidence rate of 0.87 per 100 person-years in allopurinol and 1.39 in benzbromarone initiators, showing a HR of 0.64 (95% CI, 0.51-0.80). Approximately 44% of urinary stones required intervention with a HR of 0.61 (95% CI, 0.43-0.88). The lower risk associated with allopurinol compared with benzbromarone persisted across subgroups but was greater in the high than non-high cardiovascular risk subgroup (P for interaction = 0.02). CONCLUSION: This population-based cohort study found that allopurinol compared with benzbromarone was associated with a substantially lower risk of urolithiasis particularly in the presence of the high cardiovascular risk. This finding provides important safety information for clinicians' decision-making on urate-lowering treatments of different mechanisms of action.
引用
- Kang EH, Shin A, Park CS, et al. Risk of urolithiasis associated with allopurinol versus benzbromarone among patients with gout: a population-based cohort study. Rheumatology (Oxford). 2024. PMID: 38733596. doi:10.1093/rheumatology/keae262
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。